[go: up one dir, main page]

WO2002056908A3 - Artificial antigen-presenting cells - Google Patents

Artificial antigen-presenting cells Download PDF

Info

Publication number
WO2002056908A3
WO2002056908A3 PCT/US2002/001318 US0201318W WO02056908A3 WO 2002056908 A3 WO2002056908 A3 WO 2002056908A3 US 0201318 W US0201318 W US 0201318W WO 02056908 A3 WO02056908 A3 WO 02056908A3
Authority
WO
WIPO (PCT)
Prior art keywords
artificial antigen
soluble mhc
presenting cells
presenting cell
mhc molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/001318
Other languages
French (fr)
Other versions
WO2002056908A2 (en
Inventor
William H Hildebrand
Heather D Hickman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/974,366 external-priority patent/US7541429B2/en
Priority claimed from US10/022,066 external-priority patent/US20030166057A1/en
Application filed by Individual filed Critical Individual
Priority to AU2002236777A priority Critical patent/AU2002236777A1/en
Publication of WO2002056908A2 publication Critical patent/WO2002056908A2/en
Publication of WO2002056908A3 publication Critical patent/WO2002056908A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

An artificial antigen presenting cell includes a liposome having at least onerecombinant soluble MHC-peptide complex incorporated therein. The artificialantigen presenting cell may also include at least one additional signal moleculeincorporated therein for manipulating the intensity and quality of the immune response. The recombinant soluble MHC molecule is obtained by a methodutilizing PCR amplification of gDNA or cDNA, and a tag is attached thereto foranchoring the recombinant soluble MHC molecule to the lipsome.
PCT/US2002/001318 2001-01-16 2002-01-16 Artificial antigen-presenting cells Ceased WO2002056908A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002236777A AU2002236777A1 (en) 2001-01-16 2002-01-16 Artificial antigen-presenting cells

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US26197801P 2001-01-16 2001-01-16
US60/261,978 2001-01-16
US27460501P 2001-03-09 2001-03-09
US60/274,605 2001-03-09
US09/974,366 2001-10-10
US09/974,366 US7541429B2 (en) 2000-10-10 2001-10-10 Comparative ligand mapping from MHC positive cells
US10/022,066 US20030166057A1 (en) 1999-12-17 2001-12-18 Method and apparatus for the production of soluble MHC antigens and uses thereof
US10/022,066 2001-12-18

Publications (2)

Publication Number Publication Date
WO2002056908A2 WO2002056908A2 (en) 2002-07-25
WO2002056908A3 true WO2002056908A3 (en) 2003-02-27

Family

ID=27487067

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/001318 Ceased WO2002056908A2 (en) 2001-01-16 2002-01-16 Artificial antigen-presenting cells

Country Status (1)

Country Link
WO (1) WO2002056908A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
CA2858115A1 (en) 2011-12-09 2013-06-13 The Johns Hopkins University Artificial antigen presenting cells having a defined and dynamic shape

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011702A1 (en) * 1993-10-25 1995-05-04 Anergen, Inc. Prokaryotic expression of mhc proteins
WO1997046256A1 (en) * 1996-05-23 1997-12-11 The Scripps Research Institute Mhc class ii antigen-presenting systems and methods for activating cd4+ t cells
WO2000023053A2 (en) * 1998-10-20 2000-04-27 Salvatore Albani Artificial antigen-specific cells and related methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011702A1 (en) * 1993-10-25 1995-05-04 Anergen, Inc. Prokaryotic expression of mhc proteins
WO1997046256A1 (en) * 1996-05-23 1997-12-11 The Scripps Research Institute Mhc class ii antigen-presenting systems and methods for activating cd4+ t cells
WO2000023053A2 (en) * 1998-10-20 2000-04-27 Salvatore Albani Artificial antigen-specific cells and related methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HILDEBRAND W ET AL: "Production and application of individual HLA proteins.", HUMAN IMMUNOLOGY, vol. 61, no. Supplement 2, 2000, 26th Annual Meeting of the American Society for Histocompatibility and Immunogenetics;Lake Buena Vista, Florida, USA; October 10-14, 2000, pages S81, XP008007733, ISSN: 0198-8859 *
JIANG WEIDONG ET AL: "Peptide/MHC monomers can be inserted into artificial lipid bilayers as artificial antigen presentation constructs.", BLOOD, vol. 98, no. 11 Part 1, 16 November 2001 (2001-11-16), 43rd Annual Meeting of the American Society of Hematology, Part 1;Orlando, Florida, USA; December 07-11, 2001, November 16, 2001, pages 509a, XP001074308, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
WO2002056908A2 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
EP2278022A3 (en) Expression vectors, transfection systems, and method of use thereof
EP2341072A3 (en) Method for Generating Activated T-Cells and Antigen-Pulsed Antigen-Presenting Cells
WO2001094944A3 (en) Artificial antigen presenting cells and methods of use thereof
WO2003049783A3 (en) Device and methods for harvesting tissue samples of known geometry
AU2002249531A1 (en) Immunotherapy based on dendritic cells
WO2003045427A3 (en) Pharmaceutical composition for inducing an immune response in a human or animal
WO2004093808A3 (en) Novel tumor-associated antigens
EP1288931A3 (en) Optical recording article
WO2004084838A3 (en) Identification, quantification, and characterization of t cells and t cell antigens
AU4423799A (en) Methods and agents for modulating the immune response and inflammation involvingmonocyte and dendritic cell membrane proteins
WO2001074855A3 (en) Compositions and methods for dendritic cell-based immunotherapy
WO2000009677A3 (en) Sterol-regulated site-1 protease and assays of modulators thereof
AU2003291934A1 (en) Monolithically integrated vertical pin photodiode used in bicmos technology
AU6930200A (en) Use of lentiviral vectors for antigen presentation in dendritic cells
WO2002056908A3 (en) Artificial antigen-presenting cells
WO2003051927A3 (en) Production of f(ab')2 fragments in mammalian cells
EP1054487A3 (en) Integrated lightweight optical bench and miniaturized laser transmitter using same
AU1457199A (en) Isolation, characterization, and identification of dendritic like cells and methods of using same
AU3305699A (en) Prostate-specific membrane antigens and methods of making and using
WO2004058186A3 (en) Formulations for pulmonary delivery
WO2000004918A3 (en) Agents for the immunotherapy of tumoral diseases
AU1657501A (en) Determining the functions and interactions of proteins by comparative analysis
AU7009600A (en) Method for obtaining dendritic cells, resulting dendritic cells and uses thereof for clinical purposes
WO2002074921A3 (en) Methods for isolating proteins expressed by dendritic cells
AU2001245838A1 (en) Soluble mast cell function associated antigen (mafa) pharmaceutical compositionsand methods of making and using them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP